Akari Therapeutics (AKTX) announced key preclinical data demonstrating the therapeutic potential of its novel ADC targeting Trop2, AKTX-101, in pancreatic cancer driven by K-Ras mutations, one of the deadliest and most treatment-resistant forms of cancer. The latest data for AKTX-101 in KRas-G12V PDAC builds on preclinical evidence disclosed earlier in a patent filing. In this new study, AKTX-101 exhibited single digit nanomolar cytotoxic potency in all K-Ras G12V PDAC cell lines tested. Of significance, AKTX-101 also outperformed daraxonrasib in multiple PDAC cell lines. The Company plans to present this preclinical data at an upcoming scientific conference and is currently advancing AKTX-101 towards a first-in-human trial, expected to initiate in late 2026, and preliminary safety and efficacy data in 2027.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKTX:
- Akari Therapeutics Prepares Investor Presentation for Conferences
- Akari Therapeutics provides update, highlights ADC payload innovation
- Akari Therapeutics Faces Nasdaq Delisting Notice
- Akari Therapeutics appoints Farag as interim CFO
- Akari Therapeutics announces presentation of mechanism of action data for PH1